Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

TD-4208

 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
Pharmacodynamics, pharmacokinetics and safety of revefenacin (TD-4208), a long-acting muscarinic antagonist, in patients with chronic obstructive pulmonary disease (COPD): Results of two randomized…
BACKGROUND Revefenacin (TD-4208) is a potent, lung-selective, long-acting muscarinic antagonist currently in development as a… Expand
  • figure 1
  • table 1
  • figure 2
  • figure 3
  • table 2
2018
2018
Pharmacological properties of revefenacin (TD‐4208), a novel, nebulized long‐acting, and lung selective muscarinic antagonist, at human recombinant muscarinic receptors and in rat, guinea pig, and…
Revefenacin (TD‐4208) is a novel, long‐acting, and lung‐selective muscarinic cholinergic receptor (mAChR) antagonist in… Expand
Review
2017
Review
2017
Long acting muscarinic antagonists for the treatment of chronic obstructive pulmonary disease: a review of current and developing drugs
ABSTRACT Introduction: Long acting muscarinic receptor antagonists (LAMA) reverse airflow obstruction by antagonizing para… Expand
2014
2014
Repeated-dose pharmacokinetics of once-daily TD-4208, a long-acting muscarinic receptor antagonist (LAMA), in subjects with COPD
Introduction TD-4208 is a lung-selective, LAMA shown to have a long duration of action and minimal systemic antimuscarinic… Expand
2013
2013
In Vivo Pharmacological Characterization of TD-4208, a Novel Lung-Selective Inhaled Muscarinic Antagonist with Sustained Bronchoprotective Effect in Experimental Animal Models
Tiotropium is currently the only once-daily, long-acting muscarinic antagonist (LAMA) approved in the United States and other… Expand
  • figure 2
  • table 1
  • figure 3
  • table 2
  • figure 4
Review
2013
Review
2013
Long-acting muscarinic receptor antagonists for the treatment of respiratory disease.
The use of muscarinic receptor antagonists in the treatment of chronic obstructive pulmonary disease (COPD) is well established… Expand
2012
2012
A randomized, crossover study to examine the pharmacodynamics and safety of a new antimuscarinic (TD-4208) in COPD
Background: TD-4208 is a potent and selective inhaled muscarinic antagonist with functional lung selectivity and long duration in… Expand
2009
2009
In Vitro Characterization of TD-4208, a Lung-Selective and Long-Acting Muscarinic Antagonist Bronchodilator.
 
2009
2009
TD-4208: A Novel, Lung-Selective Muscarinic Antagonist with Sustained Bronchoprotective Activity in Preclinical Models.
 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License
ACCEPT & CONTINUE